• Asian Pacific Journal of Cancer Prevention
• /
• 제15권4호
• /
• pp.1797-1802
• /
• 2014

Background: The prostaglandin-endoperoxide synthase 2 (PTGS2) and phospholipase A2 group IIA (PLA2G2A) genes encode enzymes that are involved in arachidonic acid and prostaglandin biosynthesis. Dysregulation of both genes is associated with inflammation and carcinogenesis, including esophageal squamous cell carcinoma (ESCC). We therefore hypothesized that there is an association between single nucleotide polymorphisms (SNPs) in these genes and susceptibility to ESCC. Methods: We performed a gene-wide tag SNP-based association study to examine the association of SNPs in PTGS2 and PLA2G2A with ESCC in 269 patients and 269 healthy controls from Taihangshan Mountain, Henan and Hebei Provinces, the rural area of China which has the highest incidence of esophageal cancer in the world. Thirteen tag SNPs in PLA2G2A and 4 functional SNPs in PTGS2 were selected and genotyped using a high-throughput Mass Array genotyping platform. Results: We found a modest increased risk of ESCC in subjects with the PTGS2 rs12042763 AA genotype (OR=1.23; 95% CI, 1.00-3.04) compared with genotype GG. For PLA2G2A, a decreased risk of ESCC was observed in subjects with the rs11677 CT (OR=0.51, 95%CI, 0.29-0.85) or TT genotype (OR=0.51, 95%CI, 0.17-0.96) or the T carriers (CT+TT) (OR=0.52, 95%CI, 0.31-0.85) when compared with the CC genotype. Also for PLA2G2A, rs2236771 C allele carriers were more frequent in the control group (P=0.02). Subjects with the GC (OR=0.55, 95%CI, 0.33-0.93) or CC genotype (OR=0.38, 95% CI, 0.16-0.94) or the C carriers (GC+CC) (OR=0.52, 95%CI, 0.32-0.85) showed a negative association with ESCC susceptibility. Conclusions: Our results suggest that PTGS2 and PLA2G2A gene polymorphisms may modify the risk of ESCC development.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권18호
• /
• pp.7849-7855
• /
• 2014

Purpose: To investigate the effect of deacetylase inhibitory trichostatin A (TSA) on anti HepG2 liver carcinoma cells and explore the underlying mechanisms. Materials and Methods: HepG2 cells exposed to different concentrations of TSA for 24, 48, or 72h were examined for cell growth inhibition using CCK8, changes in cell cycle distribution with flow cytometry, cell apoptosis with annexin V-FTIC/PI double staining, and cell morphology changes under an inverted microscope. Expression of ${\beta}$-catenin, HDAC1, HDAC3, H3K9, CyclinD1 and Bax proteins was tested by Western blotting. Gene expression for ${\beta}$-catenin, HDAC1and HDAC3 was tested by q-PCR. ${\beta}$-catenin and H3K9 proteins were also tested by immunofluorescence. Activity of Renilla luciferase (pTCF/LEF-luc) was assessed using the Luciferase Reporter Assay system reagent. The activity of total HDACs was detected with a HDACs colorimetric kit. Results: Exposure to TSA caused significant dose-and time-dependent inhibition of HepG2 cell proliferation (p<0.05) and resulted in increased cell percentages in G0/G1 and G2/M phases and decrease in the S phase. The apoptotic index in the control group was $6.22{\pm}0.25%$, which increased to $7.17{\pm}0.20%$ and $18.1{\pm}0.42%$ in the treatment group. Exposure to 250 and 500nmol/L TSA also caused cell morphology changes with numerous floating cells. Expression of ${\beta}$-catenin, H3K9and Bax proteins was significantly increased, expression levels of CyclinD1, HDAC1, HDAC3 were decreased. Expression of ${\beta}$-catenin at the genetic level was significantly increased, with no significant difference in HDAC1and HDAC3 genes. In the cytoplasm, expression of ${\beta}$-catenin fluorescence protein was not obvious changed and in the nucleus, small amounts of green fluorescence were observed. H3K9 fluorescence protein were increased. Expression levels of the transcription factor TCF werealso increased in HepG2 cells following induction by TSA, whikle the activity of total HDACs was decreased. Conclusions: TSA inhibits HDAC activity, promotes histone acetylation, and activates Wnt/${\beta}$-catenin signaling to inhibit proliferation of HepG2 cell, arrest cell cycling and induce apoptosis.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권2호
• /
• pp.909-913
• /
• 2013

Purpose: The liver is the organ to which colorectal carcinomas (CRCs) most commonly metastasize, and surgical resection has been established as the most effective and potentially curative treatment for CRC with liver metastasis (LM). Therefore, surveillance of LM is vital for improvement of prognosis of CRC patients. In this study, we aimed to explore the potential value of carbohydrate antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), and marker enzymes in indicating LM with CRC. Methods: Three groups of eligible patients with metastatic cancers were retrospectively included: CRC patients with LM (CRC-LM) or without LM (CRC-NLM), and non-CRC patients with LM (NCRC-LM). All metastatic lesions were identified by CT or MRI. Data on characteristics of the patients, the primary site, the locations of metastasis, CA 19-9, CEA, and biochemical parameters were collected for analysis. Results: A total of 493 patients were retrospectively included. More alcohol consumption was found in CRC-LM than CRC-NLM. Some biochemical enzymes were found to be significantly higher in groups with LM than without (CRC-LM or NCRC-LM v.s CRC-NLM). Both CEA and CA 19-9 were much higher in CRC-LM than CRC-NLM or NCRC-LM. For CRC patients, CA 19-9, ${\gamma}$-glutamyl transpeptidase, CEA and alcohol consumption were identified as independent factors associated with LM. Conclusion: Our analysis suggested the CA 19-9 might be a potential valuable indicator for LM of CRC in the clinic.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권23호
• /
• pp.10445-10449
• /
• 2015

Objective: To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Methods: Patients confirmed pathologically with cancer and complicated with moderate to severe pain, were divided into control and experimental groups. Oxycodone prolonged-release tablets, with or without fluvoxamine, were administrated to all study patients until pain relief. Degree of pain relief, dose of oxycodone prolonged-release tablets, side effects and quality of life were compared before and after treatment. Results: In total, 120 patients were recruited. No statistically significant difference was detected regarding age, gender, types of cancer, KPS between two groups of patients (P>0.05). Baseline pain score of patients with moderate pain in treatment and control group was $4.9{\pm}0.8$ and $5.1{\pm}0.8$, respectively; and decreased to $1.8{\pm}1.1$ and $1.2{\pm}1.1$ after treatment, respectively. Pain intensity was significantly reduced in the treatment group (P=0.028). Average daily consumption of oxycodone prolonged-release tablets was ($54.0{\pm}19.6$) mg and ($44.7{\pm}18.7$) mg respectively, which is lower in treatment grpup than in control group, but the difference was not statistically significant (P=0.065). Baseline pain score of patients with severe pain in treatment and control groups were $8.3{\pm}1.1$ and $8.3{\pm}1.1$, respectively; and pain intensity after treatment decreased to $2.9{\pm}1.0$ and $2.3{\pm}1.0$. Pain intensity was significantly reduced in the treatment group, with statistical significance (P=0.026). Average daily consumption of oxycodone prolonged-release tablets was ($132.0{\pm}42.2$) mg and ($110.7{\pm}33.9$) mg, respectively, which is lower in treatment group than in control group, and the difference was statistically significant (P=0.035). In terms of quality of life, patients in treatment group had better performance status, daily activity, mood, and sleep than that in control group (P < 0.05). Patients in two groups had similar side effects, eg., constipation, nausea/vomiting, lethargy, dizziness, itchy skin, dysuria, and ataxia. Lower incidence of nausea/vomiting, lethargy, was obtained from patients in treatment than in control group, while significant low constipation was observed in treatment than in control group (35.0% vs 49.2%, P=0.026). Conclusion: Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life.

• 생물환경조절학회지
• /
• 제30권1호
• /
• pp.77-84
• /
• 2021

본 연구는 산채을 활용한 어린잎 혼합 포장 상품의 개발하기 위해 기존 어린잎채소에 많이 사용되고 있는 어린잎 적로메인상추(Lactuca sativa 'Red romaine')에 어린잎 산채로 갯기름나물(Peucedanum japoincum Thunberg)과 곤달비(Ligularia stenocephala)을 혼합하여 적합한 비율을 알아보고자 수행하였다. 적로메인과 산채의 혼합비율은 적로메인0 : 갯기름5 : 곤달비5(R0:P5:L5), 적로메인3.3 : 갯기름3.3 : 곤달비3.3(R3.3:P3.3:L3.3), 적로메인5 : 갯기름2.5 : 곤달비2.5(R5:P2.5:L2.5), 적로메인8 : 갯기름1 : 곤달비1(R8:P1:L1), 적로메인10 : 갯기름0 : 곤달비0(R10:P0:L0)으로 처리하였다. 모든 처리구는 OTR(Oxygen transmission rate) 10,000cc·m-2·day-1·atm-1 필름으로 포장하여 2℃/85%RH 저온고에서 27일간 저장하며 생체중 감소율, 포장내 이산화탄소/산소/에틸렌 농도, 외관, 엽록소 함량, 색도를 조사하였다. 생체중은 R8:P1:L1 처리구가 0.4% 미만의 가장 낮은 감소율을 보였고, 이를 제외한 나머지 처리구들은 0.5% 내외의 수치를 나타내었으나 통계적 유의성은 없었다. 포장내 산소와 이산화탄소 농도는 작물의 호흡률에 영향을 받았는데, 호흡률이 낮았던 상추의 혼합비율이 높아질수록 포장내 산소농도가 높았고, 이산화탄소 농도는 낮았다. 산소농도는 15일이후 크게 감소하였으나, 16%이상은 유지되었고, 이와 반대로 이산화탄소 농도의 경우 15일까지 1-4%로 유지되다가 서서히 증가하여 27일차에는 2-5%로 증가하였다. 에틸렌 농도는 저장 종료일까지 3-6µL·L-1 내외의 농도를 유지하였다. 저장 종료일의 외관상품질은 모든처리구가 상품성 한계점인 3점에 다소 못 미치는 정도를 보였다. 엽록소 함량(SPAD)은 처리구간 통계적 유의성은 없었으나, 적로메인과 곤달비의 경우 R8:P1:L1 처리구에서, 갯기름나물은 R5:P2.5:L2.5과 R8:P1:L1처리구에서 가장 적게 감소하였다. Heat map으로 비교한 3가지 작물의 엽색(L∗, a∗, b∗, chroma)은 R5:P2.5:L2.5와 R8:P1:L1 처리구에서 저장 후 가장 변화가 적었다. 이중 R8:P1:L1 처리구는 엽록소 함량도 가장 높게 유지되었으며 포장내 에틸렌 농도도 2번째로 낮았고 이산화탄소 농도는 2-3% 수준을 유지하였다. 따라서 적로메인 8, 곤달비 1, 갯기름 1(R8:P1:L1)의 혼합한 비율이 이 3가지 작물의 어린잎 혼합 포장에 가장 적합한 것으로 판단된다.